Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

T-077

Supelco

3,3′,5-Triiodo-L-thyronine-13C6 solution

100 μg/mL in methanol with 0.1N NH3, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
13C6C9H12I3NO4
CAS Number:
1213431-76-5
Molecular Weight:
656.93
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

(Snap-N-Spike®)

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

100 μg/mL in methanol with 0.1N NH3

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

IC1=CC(O[13C]2=[13C](I)[13CH]=[13C](C[C@H](N)C(O)=O)[13CH]=[13C]2I)=CC=C1O

InChI

1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1/i3+1,4+1,7+1,10+1,11+1,14+1

InChI key

AUYYCJSJGJYCDS-HRUXDFQWSA-N

General description

A Certified Spiking Solution® of the internal standard 3,3´,5-Triiodo-L-thyronine-13C6 (T3-13C6). 3,3′,5-Triiodo-L-thyronine or T3 is a thyroid hormone involved with many physiological processes in the human body including growth and development, metabolism, body temperature and heart rate. This internal standard is suitable for quantitation of free and total T3 serum levels by LC-MS/MS for determination of hyperthyroidism caused by excess T3.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F

Flash Point(C)

9.7 °C

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hong Xia et al.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 23(8), 1648-1655 (2014-05-20)
Although direct transoral decompression and one-stage posterior instrumentation can obtain satisfactory cord decompression for the treatment of basilar invagination with atlantoaxial dislocation, surgical injuries run high as combinative anterior-posterior approaches were necessary. Furthermore, the complications will rise notably when involvement
Christina Stefanaki et al.
The Journal of dermatological treatment, 26(2), 139-142 (2014-05-20)
All available treatments for anogenital warts have substantial failure rates. An immunomodulating treatment that enhances the patient's own immunity could be valuable as an adjuvant to conventional methods. About 123 patients were enrolled in this study and were randomized either
Henry Buchwald et al.
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 10(5), 780-786 (2014-05-20)
We do not have a unified, scientifically tested theory of causation for obesity and its co-morbidities, nor do we have explanations for the mechanics of the metabolic/bariatric surgery procedures. Integral to proffered hypotheses are the actions of the hormones glucagon-like
Angie Tong et al.
Psycho-oncology, 24(1), 33-39 (2014-05-20)
Genetic testing for breast and ovarian cancer susceptibility is now part of routine clinical practice. Although rates of risk-reducing surgery following genetic testing have been increasing, little is known about attitudes toward risk-reducing surgery in women prior to genetic counseling
Nadine Tung et al.
Breast cancer research and treatment, 146(1), 175-182 (2014-05-20)
The majority of breast cancers developing in BRCA1 mutation carriers are triple negative breast cancers (TNBC), an aggressive subtype that accounts for 15-20 % of sporadic breast cancer. We compare the clinical outcome and sites of relapse of TNBC in BRCA1
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service